{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:46:30Z","timestamp":1791884790219,"version":"4.3.4"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      First, to assess the diagnostic value of fluorine-18-fluorodeoxyglucose PET-computed tomography ([\n                      <jats:sup>18<\/jats:sup>\n                      F]-FDG PET-CT) compared with conventional MRI and\/or CT. Second, to audit the clinical indications for referring patients with cervical cancer for [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FDG PET-CT against the 2022 guidelines published by the Royal College of Radiologists and the Royal College of Physicians. Finally, to evaluate the impact of [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FDG PET-CT on management plans.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study of 49 patients with histologically proven cervical cancer across the Sussex Cancer Network underwent 59 [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FDG PET-CT between 1 November 2020 and 31 October 2022. Scans were compared with the most recent CT and MRI scan conducted within 4 months of the [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FDG PET-CT. Scan indications were categorized as either \u2018in accordance\u2019 or \u2018outside\u2019 the guidelines. Those in accordance fell into one of four groups: staging, response assessment, suspected recurrence, or staging when considering exenterative surgery. A questionnaire investigating the impact of the [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FDG PET-CT on the management plan of each patient was answered by one clinical oncology consultant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FDG PET-CT identified new metastatic sites in 16\/59 (27.1%) scans. The remaining scans were concordant with the CT and MRI. The majority, 57\/59 (96.6%), of the scans were performed in accordance with the guidelines. The management plan was changed by 5\/59 scans (8.4%), confirmed by 48\/59 (81.4%) and was not impacted with 6\/59 (10.2%) scans.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FDG PET-CT is superior to conventional imaging and enhances the management plan. Future cohort studies with larger patient numbers involving multicentric studies are needed to fully assess its impact on cervical cancer management and prognosis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002248","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:01:00Z","timestamp":1791882060000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The impact and value of [18F]-FDG PET-CT on management of patients with cervical cancer with service evaluation audited against national evidence-based PET-CT guidelines"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7509-1395","authenticated-orcid":false,"given":"Maged","family":"Elsewafy","sequence":"first","affiliation":[{"name":"Nuclear Medicine Department, University Hospitals Sussex NHS Foundation Trust, Royal Sussex County Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Knox","sequence":"additional","affiliation":[{"name":"Brighton and Sussex Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamani","family":"Punchihewa","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, University Hospitals Sussex NHS Foundation Trust, Royal Sussex County Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Amro","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, University Hospitals Sussex NHS Foundation Trust, Royal Sussex County Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Lankester","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, University Hospitals Sussex NHS Foundation Trust, Royal Sussex County Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Kaushik","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, University Hospitals Sussex NHS Foundation Trust, Royal Sussex County Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitasha","family":"Singh","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, University Hospitals Sussex NHS Foundation Trust, Royal Sussex County Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Dizdarevic","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, University Hospitals Sussex NHS Foundation Trust, Royal Sussex County Hospital"},{"name":"Brighton and Sussex Medical School"},{"name":"Clinical Imaging Sciences Centre, Falmer Campus, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"R3-20261013","doi-asserted-by":"crossref","first-page":"1356581","DOI":"10.3389\/fonc.2024.1356581","article-title":"Molecular aspects of cervical cancer: a pathogenesis update.","volume":"14","author":"Vallejo-Ruiz","year":"2024","journal-title":"Front Oncol"},{"key":"R5-20261013","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3390\/cancers16040775","article-title":"The role of imaging in cervical cancer staging: ESGO\/ESTRO\/ESP Guidelines (Update 2023).","volume":"16","author":"Fischerova","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R6-20261013","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13244-023-01589-1","article-title":"Diagnostic accuracy of MRI, CT, and [18F]FDG-PET-CT in detecting lymph node metastases in clinically early-stage cervical cancer - a nationwide Dutch cohort study.","volume":"15","author":"Olthof","year":"2024","journal-title":"Insights Imaging"},{"key":"R7-20261013","journal-title":"Evidence-based indications for the use of PET-CT in the United Kingdom 2022"},{"key":"R8-20261013","first-page":"10536","article-title":"CT, MRI, and PET imaging features in cervical cancer staging and lymph node metastasis.","volume":"13","author":"Zhu","year":"2021","journal-title":"Am J Transl Res"},{"key":"R9-20261013","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000456006","article-title":"A comprehensive comparison of CT, MRI, positron emission tomography or positron emission tomography\/CT, and diffusion weighted imaging-MRI for detecting the lymph nodes metastases in patients with cervical cancer: a meta-analysis based on 67 studies.","volume":"82","author":"Liu","year":"2017","journal-title":"Gynecol Obstet Invest"},{"key":"R10-20261013","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1007\/s00330-020-06909-3","article-title":"Diagnostic performance of conventional and advanced imaging modalities for assessing newly diagnosed cervical cancer: systematic review and meta-analysis.","volume":"30","author":"Woo","year":"2020","journal-title":"Eur Radiol"},{"key":"R11-20261013","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ygyno.2020.08.021","article-title":"[18F]FDG-PET or PET\/CT in the evaluation of pelvic and para-aortic lymph nodes in patients with locally advanced cervical cancer: a systematic review of the literature.","volume":"159","author":"Adam","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R12-20261013","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejogrb.2020.08.020","article-title":"British Gynaecological Cancer Society (BGCS) cervical cancer guidelines: recommendations for practice.","volume":"256","author":"Reed","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R13-20261013","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1007\/s00330-020-06909-3","article-title":"Diagnostic performance of conventional and advanced imaging modalities for assessing newly diagnosed cervical cancer: systematic review and meta-analysis.","volume":"30","author":"Woo","year":"2020","journal-title":"Eur Radiol"},{"key":"R14-20261013","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00259-020-05112-2","article-title":"EANM\/SNMMI practice guideline for [18F]FDG PET\/CT external beam radiotherapy treatment planning in uterine cervical cancer v1.0.","volume":"48","author":"Adam","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-20261013","doi-asserted-by":"crossref","first-page":"6457","DOI":"10.1158\/1078-0432.CCR-21-1834","article-title":"Diagnostic accuracy of FEC-PET\/CT, FDG-PET\/CT, and diffusion-weighted MRI in detection of nodal metastases in surgically treated endometrial and cervical carcinoma.","volume":"27","author":"Rockall","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R16-20261013","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00066-024-02294-8","article-title":"Precision matters: the value of PET\/CT and PET\/MRI in the clinical management of cervical cancer.","volume":"201","author":"Zou","year":"2025","journal-title":"Strahlenther Onkol"},{"key":"R17-20261013","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ygyno.2020.08.021","article-title":"[18F]FDG-PET or PET\/CT in the evaluation of pelvic and para-aortic lymph nodes in patients with locally advanced cervical cancer: a systematic review of the literature.","volume":"159","author":"Adam","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R18-20261013","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12094-014-1204-8","article-title":"Impact of initial FDG PET\/CT in the management plan of patients with locally advanced head and neck cancer.","volume":"17","author":"Arias","year":"2014","journal-title":"Clin Transl Oncol"},{"key":"R19-20261013","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ygyno.2006.09.009","article-title":"Clinical impact of integrated PET\/CT on the management of suspected cervical cancer recurrence.","volume":"104","author":"Chung","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R20-20261013","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.crad.2014.07.006","article-title":"Clinical impact of FDG PET-CT on the management of patients with locally advanced cervical carcinoma.","volume":"69","author":"Fleming","year":"2014","journal-title":"Clin Radiol"},{"key":"R21-20261013","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.2967\/jnumed.108.055046","article-title":"Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.","volume":"49","author":"van der Veldt","year":"2008","journal-title":"J Nucl Med"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:01:02Z","timestamp":1791882062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":18,"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002248","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"2026-02-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}